ALRX, PMDP, LLBO, WDRP, SOMX, JNIP Stocks to Watch for Friday, July 24th provided by

ALRX, PMDP, LLBO, WDRP, SOMX, JNIP Stocks to Watch for Friday, July 24^th provided by

OTCPicks.com

Our Stocks to Watch tomorrow include AlphaRx Inc. (OTCBB: ALRX), Plateau Mineral Development Inc. (OTC: PMDP), Lifeline Biotechnologies Inc. (OTC: LLBO), Wanderport Corp. (OTC: WDRP), Somaxon Pharmaceuticals Inc. (Nasdaq: SOMX) and Juniper Group Inc. (OTCBB: JNIP).

Visit http://www.otcpicks.com/microcap.htm to register for our Daily Market Mover's Digest Newsletter, and Email Stock Watch Alerts.

ALPHARX INCORPORATED (OTCBB: ALRX)

"Up 38.61% on Thursday"

Detailed Quote: http://www.otcpicks.com/quotes/ALRX.php 

AlphaRx is a specialty pharmaceutical company dedicated to developing proven therapies by reformulating FDA approved and marketed drugs which through the application of its proprietary site-specific nano drug delivery technology, offers improved medical benefits and a potential for significant commercial product development.

ALRX News:

July 23 - AlphaRx Presents Positive Preclinical Data on Zysolin™ Inhalable Nanoparticles at Controlled Release Society Annual Meeting

AlphaRx, Inc. (OTCBB: ALRX) announced positive preclinical results which demonstrated that an inhaled tobramycin nanoparticle (Zysolin) formulation was a more effective treatment in animal models of acute Pseudomonas aeruginosa pneumonia when compared to inhaled and injected conventional tobramycin solutions. The data was presented recently in an oral podium session at the 36th Annual Meeting and Exposition of the Controlled Release Society in Copenhagen, Denmark.

"These are very encouraging results, as they suggest that Zysolin employed in this route of administration may be more effective, providing significant advantages over conventional drug formulations," stated Joseph Schwarz, Ph.D., Chief Scientist of AlphaRx. "We believe that building on this data, additional research will lead us toward the development of a drug that targets and eradicates intracellular pathogens, which to date, have proven to be very difficult to treat clinically."

The study results demonstrate that Zysolin is significantly efficacious in acute pneumonia animal models induced by gram negative pathogens including P. aeruginosa. In these lethality-based studies, Zysolin consistently increased survival rate to 50% over a Tobramycin treatment group, wherein all untreated animals died within 24 hours after infection. P. aeruginosa is one of the most common and lethal pathogens responsible for ventilator-associated pneumonia in intubated patients, being directly responsible for death rates approaching 40%. This data suggests that the nanoparticulate formulation of Zysolin may utilize a unique mechanism of action differentiating it from conventional formulations, enhancing antimicrobial activity against gram negative pathogens. Zysolin has the potential to be a first-in-class anti-infective nanomedicine.

The Controlled Release Society (CRS) is an international organization consisting of 3,000 members from more than fifty countries. Two-thirds of CRS membership are from the pharmaceutical industry and one-third consist of academic and government members. The CRS is the premier multidisciplinary society dedicated to the promotion of the science, technology, and innovative delivery of bio-actives for the benefit of the society.

ABOUT ZYSOLIN™

Zysolin is a Tobramycin compound, encapsulated in AlphaRx's Nano Drug Delivery Platform, intended for the adjunctive treatment of Gram-negative pneumonia in intubated and mechanically-ventilated patients. Zysolin improves the intracellular activity of Tobramycin — in layman's term, increasing the drug concentration of Tobramycin inside human macrophages, thus improving its antibacterial activity against intracellular Klebsiella, Pseudomondas aeruginosa and Staphylococcus bacterial strains in pneumonia patients. The active ingredient in Zysolin, Tobramycin, has a long-standing and proven clinical treatment record. Delivered by inhalation, using proprietary nanotechnology developed by AlphaRx, the company believes Zysolin will have an attractive safety, tolerability and efficacy profile when compared to injectible Tobramycin.

PLATEAU MINERAL DEVELOPMENT INCORPORATED (OTC: PMDP)

"Up 300.00% on Thursday"

Detailed Quote: http://www.otcpicks.com/quotes/PMDP.php 

Plateau Mineral Development, Inc. specializes in the exploration and development of energy sources. Its partner, Plateau Mineral Development LLC, has been in existence for over five years with successful new wells and rework wells selling both gas and oil.

PMDP News:

July 15 - Plateau Mineral Development, Inc. Announces Solar Collector

Plateau Mineral Development, Inc. (OTC: PMDP), along with its partner, Plateau Mineral Development LLC, announced today that the firm, in conjunction with MEI, is moving to secure several features of its improved solar collector.

The unit, produced and installed in the early 1980s, is being upgraded with the inclusion of photo-voltaic capability. The unit acts as a concentrator under clear skies and as a flat plate when sunlight is diffused by dust or clouds.

A representative of Plateau Mineral Development states, "Additionally, a research and development plan and budget have been prepared to research means of enhancing the photo-voltaic output. Understandably, aspects of this research and development are being held in strictest confidence. We will update our shareholders on portions of the research that are deemed appropriate for dissemination as soon as the details are available to us."

LIFELINE BIOTECHNOLOGIES INCORPORATED (OTC: LLBO)

"Up 108.96% on Thursday"

Detailed Quote: http://www.otcpicks.com/quotes/LLBO.php

Lifeline Biotechnologies, Inc. operates as a medical technology company in the United States. Its technologies focus on prevention, early detection, diagnosis, and quick recovery of various disease conditions. The company is developing a non-imaging technology, known as the First Warning System, which measures tissue activity for the early detection of breast cancer in women.

LLBO News:

July 8 - Lifeline Biotechnologies' Subsidiary, First Warning Systems, Completes Private Placement

Lifeline Biotechnologies, Inc. (OTC: LLBO) announced that its First Warning Systems™ subsidiary completed a Series A private placement of $125,000.

Jim Holmes, Lifeline’s CEO, said that “Lifeline’s subsidiary, First Warning Systems, Inc., has completed a private placement of promissory notes in the amount of $125,000. The promissory notes, due in mid-2010, are convertible into common stock of First Warning Systems, Inc. This initial funding has provided us with important resources needed to move forward on our expected FDA filings. While this funding was essential, we are preparing for the next round, a Series B private placement of common stock for up to $1,500,000. This amount should see us through the FDA process and clearance. With clearance by the FDA, we would expect to be ready for the process of market introduction of the First Warning System™.”

Holmes said, “First Warning Systems, Inc., has retained a firm specialized in FDA filings to assist in the preparation of its preliminary filing with the FDA. We expect the filing to be completed this month. The FDA’s response to this initial filing could take several months to receive. We expect the FDA’s response to give us guidance for the subsequent filing required in order to obtain marketing clearance for this proprietary process.”

Lifeline Biotechnologies has in the past year filed for a patent on the recent technological advancements of the First Warning System™, which has achieved the robust capability of identifying and classifying tissue abnormalities of the breast with sensitivities (ability to identify) of 95% to 100% and specificities (verify) of 87% to 90%. Currently, it is a well-known fact that mammograms are missing an estimated 20% to 30% of the breast cancers.

WANDERPORT CORPORATION (OTC: WDRP)

"Up 122.22% on Thursday"

Detailed Quote: http://www.otcpicks.com/quotes/WDRP.php 

Wanderport Corporation is a holding and business development company specializing in the investment and deployment of environmentally friendly technology such as, primary alternative renewable energy and energy saving products like electric vehicles which reduce global dependence on oil.

WDRP News:

July 22 - Wanderport Signs a Definitive Agreement to Acquire the Exclusive Rights to Pulsar Revolutionary Water Heater Technology

Wanderport Corp. (OTC: WDRP) announced that it has concluded a definitive agreement with the founder and holder of the intellectual property and trademark of Pulsar Advanced Technologies for the acquisition of the exclusive global sales and marketing, licensing and distribution rights to Pulsar's TIPTA award winning tank-less hot water heater technology.

Wanderport's substantial investment to acquire Pulsar's intellectual property, trademark and worldwide rights enables Wanderport to achieve the company's "Growth by Green" business model. "It is a natural synergy making Wanderport poised to become a global innovator in the billion dollar water heater industry," said Mr. Barry Somervail, President and CEO of Wanderport. Mr. Somervail continued by saying, "The acquisition is a clear indication to shareholders that Wanderport now has its own product which increases the company's financial position based on market cap, whilst potentially revolutionizing an industry with its solution that saves clean drinking water and greatly decreases energy consumption."

"I am very pleased to be working with Wanderport whose 'Green' business model will take full advantage of Pulsar's environmental benefits. I am very optimistic that our association will permit us to further develop the product and to bring to market and develop strong sales of Pulsar units locally and internationally," said Mr. Robert Simoneau, Founder of Pulsar Advanced Technologies. "Pulsar's energy efficient, continuous and on demand electric technology is based on microwave energy providing a continuous supply of heated water and fills a market niche that has not yet been converted to more efficient and environmentally friendly 'Green' tank-less methods or products," further added Mr. Simoneau.

Pulsar Advanced Technologies was the proud recipient of the 2005 TIPTA award (TCA; Toronto Construction association, Innovative Product and Technology Award), recognizing excellence in innovation in product or technology development, or its application.

SOMAXON PHARMACEUTICALS INCORPORATED (NASDAQ: SOMX)

"Up 94.38% on Thursday"

Detailed Quote: http://www.otcpicks.com/quotes/SOMX.php

Headquartered in San Diego, CA, Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the in-licensing and development of proprietary product candidates for the treatment of diseases and disorders in the fields of psychiatry and neurology. A New Drug Application (NDA) for Silenor® (doxepin), Somaxon’s drug candidate for insomnia, has been filed with the U.S. Food and Drug Administration and currently is under review.

SOMX News:

July 8 - Somaxon Pharmaceuticals Completes $6 Million Private Equity Financing

Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX), a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today said it has completed its previously announced private placement of approximately 5.1 million shares of its common stock at a price of $1.05 per share and seven-year warrants to purchase up to approximately 5.1 million additional shares of its common stock, exercisable in cash or by net exercise at a price of $1.155 per share, for aggregate gross proceeds of approximately $6 million. The price paid for the common stock is equal to the consolidated closing bid price on the Nasdaq Capital Market on the day of pricing, July 2, 2009.

The securities sold in this private placement have not been registered under the Securities Act of 1933, as amended, or any state securities laws, and were sold in a private placement pursuant to Regulation D of the Securities Act. The securities may not be offered or sold in the United States except via registration or pursuant to an exemption from the registration requirements of the Securities Act and applicable state securities laws. The company has agreed to file a registration statement covering the resale of the shares of common stock acquired by the investors and shares of common stock issuable upon exercise of the warrants acquired by the investors.

JUNIPER GROUP INCORPORATED (OTCBB: JNIP)

"Up 50.00% on Thursday"

Detailed Quote: http://www.otcpicks.com/quotes/JNIP.php

Juniper Group, Inc., through its subsidiaries, provides broadband installation and wireless infrastructure services in the United States. Its services include deployment of wireless/tower systems; maintenance and upgrading of wireless telecommunications sites; and site surveys, co-location facilitation, tower construction and antenna installation to tower system integration, and hardware and software installations. The company offers its services primarily to telecommunication companies. Juniper Group also engages in the acquisition, exploitation, and distribution of rights to films for various media, such as DVD, satellite, home video, pay-per view, pay television, television, and independent syndicated television stations. The company was founded in 1987 and is headquartered in Boca Raton, Florida.

JNIP News:

July 7 - Juniper Group Announces Another Foothold in Southern New England Market

Juniper Group, Inc. (OTCBB: JNIP) announced today that its wholly-owned telecommunications subsidiary has been tapped for work in Rhode Island, thereby enlarging their footprint in this burgeoning market.

It is expected that this work will begin imminently, and will focus primarily on tower modifications.

Vlado P Hreljanovic, President and CEO said, “Our growing presence in this market is very gratifying. It confirms that our clients appreciate our hard work and dedication to excellence. And, it illustrates once more that our crews and staff make customer satisfaction an ultimate goal.”

OTCPicks.com is located at 3533 Twin Lakes Drive, Prosper, TX 75078, Telephone: (972) 546-3740, Email: Publisher@OTCPicks.com.This email address is being protected from spam bots, you need Javascript enabled to view it.

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. OTCPicks.com makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. You are receiving this email because you have registered on OTCPicks.com or one of our affiliate companies.

The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any company profiled based solely on information contained in our reports. Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research.

Any individual who chooses to invest in any securities should do so with caution. Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested. Always research your own investments and consult with a registered investment advisor or licensed stockbroker before investing.

Information contained in our report will contain "forward looking statements" as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Subscribers are cautioned not to place undue reliance upon these forward-looking statements. These forward-looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated. Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company's most recent reports or registration statements filed with the SEC. You should consider these factors in evaluating the forward-looking statements included in the report and not place undue reliance upon such statements. We are committed to providing factual information on the companies that are profiled. However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company's plans or ability to effect any planned or proposed actions. We have no first-hand knowledge of any profiled company's operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so. Statistical information, dollar amounts, and market size data was provided by the subject company and related public information sources which we believe to be reliable but we cannot guarantee the accuracy of the information. To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information). We encourage you to invest carefully and read investment information available at the websites of the SEC at http://www.sec.gov and FINRA at http://www.finra.org.

Disclosure: OTCPicks.com has been compensated seven thousand five hundred dollars by a third party (Blue Wave Advisors) for ALRX advertising and promotional services.